

Supporting Information

Copper-Catalyzed Aerobic Oxidative Domino Cyclization of Methyl Azaarenes with 6-Amino-pyrimidine-2,4-diones and Pyrazol-5-amines: Access to Dipyrimidine/dipyrazolo-Fused Pyridines

Rong-Ji Xie,[†] Jun-Hua Liu,[†] Qiu-Yi Zhang,[†] Yi-Jie Yang,[†] Li-Qun Song, Tian-Qi Shao,
Kai-Xuan Liu and Yan-Ping Zhu*

School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation,
Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery
System and Biotech Drugs in Universities of Shandong, Yantai University, Shandong,
Yantai, 264005, P. R. China.

E-mail: chemzyp@foxmail.com; chemzyp@ytu.edu.cn

[†] These authors contributed equally to this work.

Table of Contents


1. General Information	S3
2. General Procedure for the Cyclization Process	S3
3. Control Experiments	S4
4. Characterization Data for Products	S6
5. ^1H-NMR and ^{13}C-NMR Spectra of Products	S26

1. General Information

Materials and General Experimental: Methyl quinolines were purchased from Beijing Innochem Science & Technology Co. Ltd. 6-Amino-1,3-dimethylpyrimidine-2,4-dione and aminopyrazoles, were purchased from Shanghai Shaoyuan Co. Ltd. Copper catalysts and acids were purchased from Aladdin. Unless stated otherwise, all solvents and commercially available reagents were obtained from commercial suppliers and used without further purification. In addition, petroleumether (b.p. 60-90 °C), which was used for Column chromatography, was distilled prior to use. Non-commercial starting materials were prepared as described below or according to literature procedures. Analytical thin layer chromatography (TLC) was performed using pre-coated silica gel HF254 glass plates. Column chromatography was performed using silica gel (200-300 mesh).

Instrumentation: Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Advance 400 MHz spectrometer at ambient temperature using the non or partly deuterated solvent as internal standard (^1H : δ 7.26 ppm and $^{13}\text{C}\{1\text{H}\}$: δ 77.0 ppm for CDCl_3). Chemical shifts (δ) are reported in ppm, relative to the internal standard of tetramethylsilane (TMS). The coupling constants (J) are quoted in hertz (Hz). Resonances are described as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad) or combinations thereof. High resolution mass spectra were obtained on Thermo Scientific Q-Exactive (ESI mode) Melting points were determined using SGW X-4 apparatus and not corrected.

2. General Procedure for the Cyclization Process




A 25 mL pressure vial was charged with 2-methylquinoline (**1a**) (42.9 mg, 0.30 mmol, 1.0 equiv.), 6-amino-1,3-dimethylpyrimidine-2,4-dione (**2a**) (102.5 mg, 0.66 mmol, 2.2 equiv.), Cu(OTf)₂ (21.7 mg, 0.06 mmol, 0.2 equiv.), CF₃SO₃H (45.1 mg, 0.30 mmol, 1.0 equiv.), and DMF (3.0 mL). The vial was sealed and the resulting mixture was stirred at 130 °C for 10-12 h under an O₂ atmosphere. After the reaction completed (monitored by TLC), solvent was then removed under reduced pressure and 50 mL water to the mixture, then extracted with EtOAc 3 times (3 × 50 mL). The combined organic phase was washed with 20% NaOH solution, dried over anhydrous Na₂SO₄ and concentrated in vacuum. The residue was purified by flash column chromatography on silica gel to yield the corresponding product **3aa**.

3. Control Experiments

To gain further insight into the reaction mechanism, some control experiments were conducted and the results were presented in Scheme S1. 2-Methyl quinoline **1a** could be oxidized under the standard conditions to generate quinoline-2-carbaldehyde **1aa** and 1,2-di(quinolin-2-yl)ethene **6a** in 24% and 61% yields, respectively (Scheme S1a). The reaction of 2-methyl quinoline **1a** with quinoline-2-carbaldehyde **1aa** under the standard conditions could also afford 1,2-di(quinolin-2-yl)ethane **6a** in 68% yield (Scheme S1b). The reaction of quinoline-2-carbaldehyde **1aa** with 6-amino-1,3-dimethylpyrimidine-2,4-dione **2a** could also proceed smoothly to generate product **3aa** in good yield under the standard conditions (Scheme S1c). Moreover, the reaction of quinoline-2-carbaldehyde **1aa** with 3-methyl-1-phenyl-1*H*-pyrazol-5-amine **4a** performed smoothly to afford product **5aa**.


in good yield under the standard conditions (Scheme S1d). These results confirmed that quinoline-2-carbaldehyde **1aa** is the potential intermediate for this reaction process.

Notably, some radical inhibition experiments for **1a** and **2a** were performed with a stoichiometric amount of three radical inhibitors, TEMPO, 1,1-diphenyle-thene or BHT. A trace amount of target product **3aa** was observed for these reactions (Scheme S1e). What is more, radical inhibition experiments were also conducted using **1a** and **4a** with radical inhibitors (TEMPO, 1,1-diphenyle-thene or BHT) under the standard conditions (Scheme S1f). The product **5aa** was detected in a trace amount. These results discovered that the reaction proceeds through a radical process.




Scheme S1: Control experiments.

4. Characterization Data for Products




3aa

1,3,7,9-Tetramethyl-5-(quinolin-2-yl)pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3aa), 106 mg, 83%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 8.3 Hz, 1H), 8.00 (d, *J* = 8.4 Hz, 1H), 7.91 (dd, *J* = 8.2, 1.1 Hz, 1H), 7.69 (ddd, *J* = 8.4, 7.0, 1.4 Hz, 1H), 7.55 (ddd, *J* = 8.1, 7.0, 1.2 Hz, 1H), 7.42 (d, *J* = 8.5 Hz, 1H), 3.78 (s, 6H), 3.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.0, 156.9, 156.7, 153.6, 150.8, 147.5, 135.1, 129.5, 128.9, 128.1, 127.2, 126.5, 120.2, 105.1, 30.3, 28.4. HRMS (ESI) m/z calculated for [C₂₂H₁₈N₆O₄+H]⁺ 431.1462, found 431.1450.




3ba

1,3,7,9-Tetramethyl-5-(6-methylquinolin-2-yl)pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ba), 124 mg, 92%, brown solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.5 Hz, 1H), 7.90 (d, *J* = 8.5 Hz, 1H), 7.67 (s, 1H), 7.52 (d, *J* = 8.6 Hz, 1H), 7.37 (d, *J* = 8.5 Hz, 1H), 3.78 (s, 6H), 3.24 (s, 6H), 2.54 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.0, 157.1, 155.7, 153.5, 150.8, 146.0, 136.3, 134.6, 131.8, 128.6, 127.2, 127.0, 120.1, 105.1, 30.3, 28.4, 21.5. HRMS (ESI) m/z calculated for [C₂₃H₂₀N₆O₄+H]⁺ 445.1619, found 445.1611.




3ca

5-(6-Methoxyquinolin-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ca), 120 mg, 86%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.5 Hz, 1H), 7.90 (d, *J* = 9.2 Hz, 1H), 7.39 – 7.32 (m, 2H), 7.18 (d, *J* = 2.8 Hz, 1H), 3.93 (s, 3H), 3.78 (s, 6H), 3.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 157.8, 157.1, 154.1, 153.6, 150.8, 143.5, 134.1, 130.4, 128.2, 122.1, 120.4, 106.0, 105.20, 55.6, 30.4, 28.5. HRMS (ESI) m/z calculated for [C₂₃H₂₀N₆O₅+H]⁺ 461.1568, found 461.1569.




3da

5-(6-Ethoxyquinolin-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3da), 99 mg, 69%, pink solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, *J* = 8.5 Hz, 1H), 7.90 (d, *J* = 9.1 Hz, 1H), 7.38 – 7.32 (m, 2H), 7.17 (d, *J* = 2.7 Hz, 1H), 4.17 (q, *J* = 7.0 Hz, 2H), 3.78 (s, 6H), 3.25 (s, 6H), 1.49 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 157.2, 157.2, 153.9, 153.6, 150.9, 143.4, 134.1, 130.3, 128.3, 122.5, 120.4, 106.8, 105.3, 63.8, 30.4, 28.5, 14.7. HRMS (ESI) m/z calculated for [C₂₄H₂₂N₆O₅+H]⁺ 475.1724, found 475.1718.




3ea

5-(6-Fluoroquinolin-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1*H*,3*H*,7*H*,9*H*)-tetraone (3ea), 87 mg, 64%, yellow solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.5 Hz, 1H), 8.00 (dd, *J* = 9.2, 5.3 Hz, 1H), 7.53 (dd, *J* = 8.9, 2.8 Hz, 1H), 7.50 – 7.44 (m, 1H), 7.43 (d, *J* = 8.3 Hz, 1H), 3.79 (s, 6H), 3.26 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.3, 159.1, 156.7, 156.1, 153.7, 150.8, 144.6, 134.6, 131.5, 127.9, 121.1, 119.8, 111.4, 105.1, 30.4, 28.5. HRMS (ESI) m/z calculated for [C₂₂H₁₇FN₆O₄+H]⁺ 449.1368, found 449.1359.




3fa

5-(7-Fluoroquinolin-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1*H*,3*H*,7*H*,9*H*)-tetraone (3fa), 81 mg, 60%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.5 Hz, 1H), 7.90 (dd, *J* = 9.0, 6.0 Hz, 1H), 7.63 (dd, *J* = 10.2, 2.5 Hz, 1H), 7.42 – 7.31 (m, 2H), 3.78 (s, 6H), 3.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 157.9, 153.7, 150.8, 135.3, 130.3, 130.2, 124.2, 119.7, 117.1, 116.9, 113.0, 112.7, 105.0, 30.4, 28.5. HRMS (ESI) m/z calculated for [C₂₂H₁₇FN₆O₄+H]⁺ 449.1368, found 449.1358.




3ga

5-(6-Chloroquinolin-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ga), 86 mg, 61%, brown solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.5 Hz, 1H), 7.93 (d, *J* = 8.9 Hz, 1H), 7.89 (d, *J* = 2.0 Hz, 1H), 7.62 (dd, *J* = 8.9, 2.0 Hz, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 3.79 (s, 6H), 3.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 157.2, 156.5, 153.6, 150.7, 145.9, 134.2, 132.2, 130.6, 130.4, 127.8, 126.8, 121.2, 105.0, 30.4, 28.5. HRMS (ESI) m/z calculated for [C₂₂H₁₇ClN₆O₄+H]⁺ 465.1073, found 465.1066.




3ha

5-(7-Chloroquinolin-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ha), 98 mg, 70%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.5 Hz, 1H), 8.03 (s, 1H), 7.86 (d, *J* = 8.7 Hz, 1H), 7.53 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.42 (d, *J* = 8.5 Hz, 1H), 3.79 (s, 6H), 3.26 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.2, 158.0, 156.6, 153.7, 150.8, 147.9, 135.4, 135.0, 129.4, 128.3, 127.6, 125.6, 120.6, 105.1, 30.5, 28.6. HRMS (ESI) m/z calculated for [C₂₂H₁₇ClN₆O₄+H]⁺ 465.1073, found 465.1064.




3ia

5-(6-Bromoquinolin-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ia), 118 mg, 77%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.5 Hz, 1H), 8.07 (d, *J* = 2.1 Hz, 1H), 7.87 (d, *J* = 9.0 Hz, 1H), 7.76 (dd, *J* = 8.9, 2.2 Hz, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 3.79 (s, 6H), 3.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 157.3, 156.4, 153.6, 150.8, 146.0, 134.2, 133.0, 130.7, 130.1, 128.4, 121.2, 120.4, 105.0, 30.4, 28.5. HRMS (ESI) m/z calculated for [C₂₂H₁₇BrN₆O₄+H]⁺ 509.0567, found 509.0564.



3ja


5-(Benzo[f]quinolin-3-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ia), 94 mg, 65%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 9.10 (d, *J* = 8.6 Hz, 1H), 8.68 (d, *J* = 8.5 Hz, 1H), 8.00 (d, *J* = 9.1 Hz, 1H), 7.98 – 7.91 (m, 2H), 7.74 – 7.63 (m, 2H), 7.60 (d, *J* = 8.6 Hz, 1H), 3.80 (s, 6H), 3.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 157.1, 156.2, 153.7, 150.9, 147.6, 131.8, 131.1, 130.2, 130.0, 128.6, 127.9, 127.1, 127.0, 124.4, 122.8, 120.2, 105.2, 30.5, 28.5. HRMS (ESI) m/z calculated for [C₂₆H₂₀N₆O₄+H]⁺ 481.1619, found 481.1609.



3ka

1,3,7,9-Tetramethyl-5-(quinolin-4-yl)pyrido[2,3-d:6,5-d']dipyrimidine-


2,4,6,8(1H,3H,7H,9H)-tetraone (3ka), 41 mg, 31%, orange solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.97 (d, *J* = 4.4 Hz, 1H), 8.21 (d, *J* = 8.4 Hz, 1H), 7.68 (ddd, *J* = 8.4, 6.8, 1.4 Hz, 1H), 7.37 (ddd, *J* = 8.1, 6.9, 1.2 Hz, 1H), 7.26 – 7.21 (m, 1H), 7.09 (d, *J* = 4.5 Hz, 1H), 3.82 (s, 6H), 3.19 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.3, 155.1, 153.6, 150.7, 149.5, 147.2, 145.6, 130.2, 129.3, 126.7, 126.2, 123.7, 117.6, 105.1, 30.5, 28.5. HRMS (ESI) m/z calculated for [C₂₂H₁₈N₆O₄+H]⁺ 431.1462, found 431.1454.



3la


5-(Isoquinolin-1-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-

2,4,6,8(1H,3H,7H,9H)-tetraone (3la), 85 mg, 65%, brown solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, *J* = 5.7 Hz, 1H), 7.94 (d, *J* = 8.3 Hz, 1H), 7.78 (d, *J* = 5.7 Hz, 1H), 7.66 (ddd, *J* = 8.2, 6.3, 1.7 Hz, 1H), 7.46-7.34 (m, 2H), 3.82 (s, 6H), 3.20 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.6, 157.7, 155.9, 153.8, 150.9, 141.9, 135.2, 130.0, 127.5, 127.3, 127.1, 124.5, 120.5, 105.6, 30.4, 28.5. HRMS (ESI) m/z calculated for [C₂₂H₁₈N₆O₄+H]⁺ 431.1462, found 431.1454.




3ma

1,3,7,9-Tetramethyl-5-(1,8-naphthyridin-2-yl)pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ma), 102 mg, 78%, brown solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 9.08 (dd, *J* = 3.9, 1.5 Hz, 1H), 8.30 (d, *J* = 8.4 Hz, 2H), 7.57 (d, *J* = 8.4 Hz, 1H), 7.53 (dd, *J* = 8.0, 4.2 Hz, 1H), 3.80 (s, 6H), 3.24 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 160.6, 159.2, 156.1, 155.6, 153.6, 153.2, 150.8, 137.6, 135.7, 122.2, 121.9, 121.8, 105.2, 30.5, 28.5. HRMS (ESI) m/z calculated for [C₂₁H₁₇N₇O₄+H]⁺ 432.1415, found 432.1408.



3na


1,3,7,9-Tetramethyl-5-(quinoxalin-2-yl)pyrido[2,3-d:6,5-d']dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetraone (3ma), 50 mg, 39%, red solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 8.24-8.17 (m, 1H), 8.01-7.95 (m, 1H), 7.80-7.71 (m, 2H), 3.79 (s, 6H), 3.25 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.3, 154.0, 153.6, 152.6, 150.7, 143.7, 141.5, 141.1, 130.0, 129.7, 129.6, 128.9, 122.8, 105.5, 30.7, 28.6. HRMS (ESI) m/z calculated for [C₂₁H₁₇N₇O₄+H]⁺ 432.1415, found 432.1430.



3oa

5-(Benzo[d]thiazol-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-


2,4,6,8(1H,3H,7H,9H)-tetraone (3oa), 31 mg, 24%, brown solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.1 Hz, 1H), 7.97 (ddd, *J* = 7.9, 1.2, 0.5 Hz, 1H), 7.52 (td, *J* = 8.2, 7.8, 1.3 Hz, 1H), 7.48 – 7.42 (m, 1H), 3.79 (s, 6H), 3.31 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 163.2, 158.5, 153.5, 152.8, 150.6, 150.1, 136.0, 126.2, 125.5, 123.5, 122.0, 105.6, 30.6, 28.7. HRMS (ESI) m/z calculated for [C₂₀H₁₆N₆O₄S+H]⁺ 437.1026, found 437.1021.



3pa

5-(Benzo[d]oxazol-2-yl)-1,3,7,9-tetramethylpyrido[2,3-d:6,5-d']dipyrimidine-


2,4,6,8(1H,3H,7H,9H)-tetraone (3pa), 32 mg, 25%, brown solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 7.85-7.78 (m, 1H), 7.70-7.63 (m, 1H), 7.45-7.40 (m, 2H), 3.80 (s, 6H), 3.33 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.6, 157.5, 153.5, 150.8, 150.6, 143.3, 141.5, 125.4, 124.7, 120.4, 111.1, 106.2, 30.5, 28.7. HRMS (ESI) m/z calculated for [C₂₀H₁₆N₆O₅+H]⁺ 421.1255, found 421.1247.



3qa

1,3,7,9-Tetramethyl-5-(pyridin-2-yl)pyrido[2,3-d:6,5-d']dipyrimidine-


2,4,6,8(1H,3H,7H,9H)-tetraone (3qa), 67 mg, 59%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.69 (d, *J* = 4.9 Hz, 1H), 7.83 (td, *J* = 7.8, 1.7 Hz, 1H), 7.42 (ddd, *J* = 7.6, 5.0, 1.1 Hz, 1H), 7.28 (t, *J* = 1.0 Hz, 1H), 3.78 (s, 6H), 3.30 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.2, 156.8, 156.2, 153.6, 150.9, 149.0, 135.6, 122.7, 121.9, 104.9, 30.4, 28.6. HRMS (ESI) m/z calculated for [C₁₈H₁₆N₆O₄+H]⁺ 381.1306, found 381.1300.



3ra

1,3,7,9-Tetramethyl-5-(pyridin-4-yl)pyrido[2,3-d:6,5-d']dipyrimidine-

2,4,6,8(1H,3H,7H,9H)-tetraone (3ra), 80 mg, 71%, white solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, *J* = 5.9 Hz, 2H), 7.07 (dd, *J* = 4.4, 1.6 Hz, 2H), 3.78 (s, 6H), 3.30 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.9, 156.2, 153.5, 150.7, 149.2, 146.6, 120.9, 104.3, 30.5, 28.6. HRMS (ESI) m/z calculated for [C₁₈H₁₆N₆O₄+H]⁺ 381.1306, found 381.1296.




5aa

3,5-Dimethyl-1,7-diphenyl-4-(quinolin-2-yl)-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridine (5aa), 124 mg, 89%, green solid, m.p. 228-230°C, ¹H NMR (400 MHz, CDCl₃)


δ 8.49 – 8.35 (m, 5H), 8.24 (d, *J* = 8.4 Hz, 1H), 8.01 (d, *J* = 8.1 Hz, 1H), 7.87 (t, *J* = 7.5 Hz, 1H), 7.71 (t, *J* = 7.2 Hz, 2H), 7.55 (t, *J* = 7.6 Hz, 4H), 7.35 – 7.27 (m, 2H), 2.05 (d, *J* = 3.8 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 153.4, 150.7, 147.4, 144.0, 139.6, 139.1, 136.3, 130.7, 129.7, 128.9, 127.9, 127.7, 127.4, 125.2, 122.1, 120.3, 113.1, 14.9. HRMS (ESI) m/z

calculated for [C₃₀H₂₂N₆+H]⁺ 467.1979, found 467.1969.




5ba

3,5-Dimethyl-4-(6-methylquinolin-2-yl)-1,7-diphenyl-1,7-dihydriopyrazolo[3,4-b:4',3'-e]pyridine (5ba), 102 mg, 71%, brown solid, m.p. 213–215°C, ¹H NMR (400 MHz, CDCl₃) δ 8.42 (dd, *J* = 8.7, 1.0 Hz, 4H), 8.31 (d, *J* = 8.3 Hz, 1H), 8.14 (d, *J* = 8.6 Hz, 1H), 7.77 (s, 1H), 7.70 (dd, *J* = 8.6, 1.8 Hz, 1H), 7.66 (d, *J* = 8.3 Hz, 1H), 7.55 (td, *J* = 7.5, 1.9 Hz, 4H), 7.33 – 7.27 (m, 2H), 2.64 (s, 3H), 2.06 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.7, 150.8, 150.6, 144.1, 143.5, 139.6, 139.3, 134.9, 131.1, 128.9, 128.7, 125.1, 123.7, 122.4, 120.3, 113.2, 105.1, 55.7, 14.9. HRMS (ESI) m/z calculated for [C₃₁H₂₄N₆+H]⁺ 481.2135, found 481.2130.




5ca

4-(6-Methoxyquinolin-2-yl)-3,5-dimethyl-1,7-diphenyl-1,7-dihydriopyrazolo[3,4-b:4',3'-e]pyridine (5ca), 126 mg, 85%, white solid, m.p. 262–263°C, ¹H NMR (400 MHz, CDCl₃) δ 8.45 – 8.41 (m, 4H), 8.28 (d, *J* = 8.3 Hz, 1H), 8.13 (d, *J* = 9.2 Hz, 1H), 7.65 (d, *J* = 8.3 Hz, 1H), 7.57 – 7.50 (m, 5H), 7.29 (t, *J* = 7.4 Hz, 2H), 7.24 (d, *J* = 2.6 Hz, 1H), 4.01 (s, 3H), 2.06 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.1, 150.8, 150.6, 144.1, 143.5, 139.7, 139.5, 134.9, 131.1, 128.9, 128.7, 125.2, 123.9, 122.3, 120.4, 113.3, 105.8, 64.0, 14.9. HRMS (ESI) m/z calculated for [C₃₁H₂₄N₆O+H]⁺ 497.2084, found 497.2075.




5da

4-(6-Ethoxyquinolin-2-yl)-3,5-dimethyl-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5da), 106 mg, 69%, green solid, m.p. 279-281°C, ¹H NMR (400 MHz, CDCl₃) δ 8.42 (dd, *J* = 8.7, 1.1 Hz, 4H), 8.27 (d, *J* = 8.3 Hz, 1H), 8.11 (d, *J* = 9.2 Hz, 1H), 7.63 (d, *J* = 8.3 Hz, 1H), 7.57 – 7.49 (m, 5H), 7.32–7.27 (m, 2H), 7.23 (d, *J* = 2.7 Hz, 1H), 4.24 (q, *J* = 7.0 Hz, 2H), 2.07 (s, 6H), 1.55 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 158.1, 150.8, 150.6, 144.1, 143.4, 139.6, 139.4, 134.9, 131.1, 129.0, 128.7, 125.2, 124.0, 122.3, 120.4, 113.2, 105.8, 64.0, 14.9, 14.7. HRMS (ESI) m/z calculated for [C₃₂H₂₆N₆O+H]⁺ 511.2241, found 511.2233.




5ea

4-(6-Fluoroquinolin-2-yl)-3,5-dimethyl-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5ea), 101 mg, 70%, green solid, m.p. 236-237°C, ¹H NMR (400 MHz, CDCl₃) δ 8.44-8.39 (m, 4H), 8.34 (d, *J* = 8.4 Hz, 1H), 8.25 (dd, *J* = 9.1, 5.3 Hz, 1H), 7.72 (d, *J* = 8.3 Hz, 1H), 7.67-7.60 (m, 2H), 7.57-7.52 (m, 4H), 7.33-7.27 (m, 2H), 2.04 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 159.9, 152.7, 150.7, 144.4, 143.8, 139.5, 138.5, 135.8, 132.3, 129.0, 128.3, 125.3, 122.9, 121.4, 120.4, 113.0, 111.1, 14.9. HRMS (ESI) m/z calculated for [C₃₀H₂₁FN₆+H]⁺ 485.1884, found 485.1876.




5ga

4-(6-Chloroquinolin-2-yl)-3,5-dimethyl-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5ga), 108 mg, 72%, yellow solid, m.p. 227-229°C, ¹H NMR (400 MHz, CDCl₃) δ 8.43-8.39 (m, 4H), 8.26 (d, *J* = 8.3 Hz, 1H), 8.16 (d, *J* = 9.0 Hz, 1H), 7.98 (d, *J* = 2.3 Hz, 1H), 7.79 (dd, *J* = 9.0, 2.3 Hz, 1H), 7.72 (d, *J* = 8.4 Hz, 1H), 7.57-7.51 (m, 4H), 7.32-7.27 (m, 2H), 2.01 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 153.7, 150.6, 145.8, 143.7, 139.5, 138.6, 135.3, 133.6, 131.7, 131.3, 128.9, 128.0, 126.5, 125.2, 123.0, 120.3, 112.9, 14.9. HRMS (ESI) m/z calculated for [C₃₀H₂₁ClN₆+H]⁺ 501.1589, found 501.1585.




5ia

4-(6-Bromoquinolin-2-yl)-3,5-dimethyl-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5ia), 115 mg, 70%, yellow solid, m.p. 213-215°C, ¹H NMR (400 MHz, CDCl₃) δ 8.41 (dd, *J* = 8.6, 1.0 Hz, 4H), 8.27 (d, *J* = 8.4 Hz, 1H), 8.16 (d, *J* = 2.1 Hz, 1H), 8.09 (d, *J* = 9.0 Hz, 1H), 7.93 (dd, *J* = 8.9, 2.2 Hz, 1H), 7.72 (d, *J* = 8.4 Hz, 1H), 7.54 (td, *J* = 7.5, 1.8 Hz, 4H), 7.33 – 7.26 (m, 2H), 2.02 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 153.9, 150.7, 146.0, 143.7, 139.5, 138.6, 135.2, 134.3, 131.4, 129.9, 128.9, 128.5, 125.3, 123.0, 121.9, 120.3, 112.9, 14.9. HRMS (ESI) m/z calculated for [C₃₀H₂₁BrN₆+H]⁺ 545.1084, found 545.1076.




3-(3,5-Dimethyl-1,7-diphenyl-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridin-4-yl)benzo[f]quinoline (5ja), 127 mg, 82%, white solid, m.p. 279–280°C, ¹H NMR (400 MHz, CDCl₃) δ 9.20 (d, *J* = 8.4 Hz, 1H), 8.77 (d, *J* = 8.0 Hz, 1H), 8.46 – 8.42 (m, 4H), 8.17 – 8.10 (m, 2H), 8.05 (dd, *J* = 7.9, 1.3 Hz, 1H), 7.87 (d, *J* = 8.4 Hz, 1H), 7.85 – 7.74 (m, 2H), 7.59 – 7.52 (m, 4H), 7.34 – 7.28 (m, 2H), 2.08 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 152.8, 150.8, 147.6, 144.1, 139.6, 139.0, 132.4, 132.1, 131.0, 129.3, 129.0, 128.1, 127.9, 127.7, 125.2, 125.1, 122.9, 122.3, 120.4, 113.2, 15.0. HRMS (ESI) m/z calculated for [C₃₄H₂₄N₆+H]⁺ 517.2135, found 517.2125.




5ka

3,5-Dimethyl-1,7-diphenyl-4-(quinolin-4-yl)-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridine (5ka), 88 mg, 63%, brown solid, m.p. 264–266°C, ¹H NMR (400 MHz, CDCl₃) δ 9.13 (d, *J* = 4.3 Hz, 1H), 8.45 – 8.39 (m, 4H), 8.32 (d, *J* = 8.5 Hz, 1H), 7.83 (ddd, *J* = 8.4, 6.8, 1.4 Hz, 1H), 7.56 (td, *J* = 7.5, 2.0 Hz, 5H), 7.51 (ddd, *J* = 8.1, 6.8, 1.2 Hz, 1H), 7.42 – 7.38 (m, 1H), 7.34 – 7.29 (m, 2H), 1.82 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 150.5, 149.2, 147.7, 143.9, 141.3, 139.4, 135.8, 130.5, 130.0, 129.0, 128.0, 127.0, 125.5, 125.4, 121.4, 120.3, 113.4, 14.2. HRMS (ESI) m/z calculated for [C₃₀H₂₂N₆+H]⁺ 467.1979, found 467.1976.




5oa

2-(3,5-Dimethyl-1,7-diphenyl-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridin-4-yl)benzo[d]thiazole (5oa), 77 mg, 55%, green solid, m.p. 214–216°C, ^1H NMR (400 MHz, CDCl_3) δ 8.43 – 8.38 (m, 4H), 8.27 (d, J = 8.2 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.68 (ddd, J = 8.3, 7.3, 1.3 Hz, 1H), 7.62 – 7.52 (m, 5H), 7.34 – 7.29 (m, 2H), 2.25 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.6, 152.9, 150.4, 143.6, 139.4, 135.8, 131.1, 129.0, 127.1, 126.4, 125.4, 124.2, 121.7, 120.4, 113.3, 14.6. HRMS (ESI) m/z calculated for $[\text{C}_{28}\text{H}_{20}\text{N}_6\text{S}+\text{H}]^+$ 473.1543, found 473.1538.




5pa

2-(3,5-Dimethyl-1,7-diphenyl-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridin-4-yl)benzo[d]oxazole (5pa), 68 mg, 50%, yellow solid, m.p. 214–216°C, ^1H NMR (400 MHz, CDCl_3) δ 8.41 – 8.37 (m, 4H), 7.99 – 7.96 (m, 1H), 7.76 – 7.72 (m, 1H), 7.58 – 7.52 (m, 6H), 7.34 – 7.28 (m, 2H), 2.45 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.7, 150.8, 150.5, 143.5, 141.2, 139.3, 129.0, 126.6, 125.5, 125.4, 124.2, 121.1, 120.5, 113.1, 111.1, 14.8. HRMS (ESI) m/z calculated for $[\text{C}_{28}\text{H}_{20}\text{N}_6\text{O}+\text{H}]^+$ 457.1771, found 457.1762.




5qa

3,5-Dimethyl-1,7-diphenyl-4-(pyridin-2-yl)-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5qa), 57 mg, 45%, green solid, m.p. 246-248°C, ¹H NMR (400 MHz, CDCl₃) δ 8.86 (s, 1H), 8.45-8.37 (m, 4H), 7.92 (t, *J* = 7.4 Hz, 1H), 7.59 (d, *J* = 7.7 Hz, 1H), 7.54 (t, *J* = 8.0 Hz, 5H), 7.29 (t, *J* = 7.4 Hz, 2H), 2.09 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 153.3, 150.7, 149.5, 143.9, 139.6, 138.7, 136.2, 128.9, 125.2, 124.8, 123.9, 120.3, 113.0, 14.7. HRMS (ESI) m/z calculated for [C₂₆H₂₀N₆+H]⁺ 417.1822, found 417.1808.



5ra


3,5-Dimethyl-1,7-diphenyl-4-(pyridin-4-yl)-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5ra), 67 mg, 53%, yellow solid, m.p. 250-252°C, ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 4.4 Hz, 2H), 8.34 (d, *J* = 7.7 Hz, 4H), 7.50 (t, *J* = 8.0 Hz, 4H), 7.43 (d, *J* = 5.3 Hz, 2H), 7.27 (t, *J* = 7.4 Hz, 2H), 2.01 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 150.1, 149.5, 143.5, 142.7, 139.3, 137.3, 128.9, 125.3, 123.7, 120.1, 112.4, 14.8. HRMS (ESI) m/z calculated for [C₂₆H₂₀N₆+H]⁺ 417.1822, found 417.1808.



5sa


4-(5-Ethylpyridin-2-yl)-3,5-dimethyl-1,7-diphenyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine

e]pyridine (5sa**),** 26 mg, 19%, white solid, m.p. 228-230°C, ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, *J* = 1.6 Hz, 1H), 8.43 – 8.38 (m, 4H), 7.75 (dd, *J* = 7.9, 2.1 Hz, 1H), 7.56 – 7.49 (m, 5H), 7.29 (tt, *J* = 7.8, 1.2 Hz, 2H), 2.84 (q, *J* = 7.6 Hz, 2H), 2.10 (s, 6H), 1.40 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 150.7, 150.4, 149.1, 144.1, 139.8, 139.6, 139.1, 135.4, 128.9, 125.1, 124.4, 120.3, 113.2, 26.0, 15.1, 14.8. HRMS (ESI) m/z calculated for [C₂₈H₂₄N₆+H]⁺ 445.2135, found 445.2121.



5ta


2-(3,5-Dimethyl-1,7-diphenyl-1,7-dihydriodipyrrolo[3,4-b:4',3'-e]pyridin-4-yl)quinazolin-4(3H)-one (5ta**),** 43 mg, 29%, yellow solid, m.p. 100-100°C, ¹H NMR (400 MHz, CDCl₃) δ 8.43 (dd, *J* = 8.0, 0.9 Hz, 1H), 8.27 (d, *J* = 7.6 Hz, 4H), 7.94 – 7.87 (m, 1H), 7.83 (d, *J* = 8.1 Hz, 1H), 7.70 – 7.62 (m, 1H), 7.45 (t, *J* = 8.0 Hz, 4H), 7.30 (d, *J* = 7.4 Hz, 3H), 2.36 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 181.6, 150.3, 143.1, 138.9, 135.5, 129.1, 128.1, 126.9, 125.6, 119.7, 111.9, 14.4. (Some signals of the carbon were missing in the spectrum because of the poor solubility of the compound **5ta**). HRMS (ESI) m/z calculated for [C₂₉H₂₁N₇O+H]⁺ 484.1880, found 484.1868.



5ab

1,3,5,7-Tetramethyl-4-(quinolin-2-yl)-1,7-dihydriodipyrrolo[3,4-b:4',3'-e]pyridine (5ab**),** 36 mg, 36%, yellow liquid, ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, *J* = 7.9 Hz, 1H), 8.24 – 8.19 (m, 1H), 7.98 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.84 (ddd, *J* = 8.4, 6.9, 1.5 Hz, 1H), 7.69 (ddd, *J* = 8.1, 6.9, 1.2 Hz, 1H), 7.62 (d, *J* = 8.3 Hz, 1H), 4.09 (s, 6H), 1.98 (s, 6H). ¹³C


NMR (101 MHz, CDCl₃) δ 154.1, 152.2, 147.4, 141.7, 138.6, 136.1, 130.6, 129.7, 127.8, 127.6, 127.4, 122.2, 111.1, 33.5, 14.8. HRMS (ESI) m/z calculated for [C₂₀H₁₈N₆+H]⁺ 343.1666, found 343.1654.



5ac

1,3,5,7-Tetraphenyl-4-(quinolin-2-yl)-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridine


(5ac), 75 mg, 43%, yellow solid, m.p. 242-244°C, ¹H NMR (400 MHz, CDCl₃) δ 8.55 (dd, *J* = 8.7, 1.1 Hz, 4H), 7.69 – 7.50 (m, 10H), 7.41 – 7.33 (m, 2H), 7.12 – 7.03 (m, 5H), 6.90 – 6.82 (m, 2H), 6.75 (t, *J* = 7.6 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 152.3, 150.9, 147.5, 146.9, 139.6, 139.6, 135.0, 132.8, 129.6, 129.3, 129.0, 128.8, 127.6, 127.3, 127.2, 127.0, 126.8, 125.8, 122.7, 121.0, 112.6. HRMS (ESI) m/z calculated for [C₄₀H₂₆N₆+H]⁺ 591.2292, found 591.2280.



5oc


2-(1,3,5,7-Tetraphenyl-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridin-4-yl)benzo[d]thiazole (5oc)

85 mg, 47%, green solid, m.p. 239-240°C, ¹H NMR (400 MHz, CDCl₃) δ 8.56-8.51 (m, 4H), 7.72-7.57 (m, 6H), 7.46-7.34 (m, 4H), 7.30-7.27 (m, 2H), 7.26-7.25 (m, 2H), 7.01-6.96 (m, 2H), 6.91-6.85 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 159.3, 152.3, 150.4, 147.2, 139.4, 136.3, 132.6, 131.9, 129.1, 128.6, 128.0, 127.5, 126.1, 126.0, 125.7, 123.7, 121.0, 120.7, 112.8. HRMS (ESI) m/z calculated for [C₃₈H₂₄N₆S+H]⁺ 597.1856, found 597.1843.




5ad

3,5-Bis(4-fluorophenyl)-1,7-diphenyl-4-(quinolin-2-yl)-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5ad), 110 mg, 66%, yellow solid, m.p. 269–270°C, ¹H NMR (400 MHz, CDCl₃) δ 8.56 – 8.50 (m, 4H), 7.74 (d, *J* = 8.3 Hz, 2H), 7.67 – 7.56 (m, 7H), 7.41 – 7.34 (m, 2H), 7.09 – 7.01 (m, 5H), 6.52 – 6.40 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 163.5, 161.0, 152.1, 150.8, 146.9, 146.4, 139.4, 135.1, 130.6, 130.0, 129.1, 129.0, 128.9, 127.6, 127.2, 126.8, 125.9, 122.6, 120.9, 114.5, 112.4. HRMS (ESI) m/z calculated for [C₄₀H₂₄F₂N₆+H]⁺ 627.2103, found 627.2091.




5ae

3,5-Diphenyl-4-(quinolin-2-yl)-1,7-di-p-tolyl-1,7-dihydrodipyrazolo[3,4-b:4',3'-e]pyridine (5ae), 96 mg, 53%, green solid, m.p. >300°C, ¹H NMR (400 MHz, CDCl₃) δ 8.44–8.37 (m, 4H), 7.65 (t, *J* = 8.5 Hz, 2H), 7.61–7.54 (m, 2H), 7.52 (ddd, *J* = 8.1, 6.0, 2.3 Hz, 1H), 7.40 (d, *J* = 8.3 Hz, 4H), 7.12–7.01 (m, 5H), 6.89–6.82 (m, 2H), 6.74 (t, *J* = 7.5 Hz, 4H), 2.48 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 152.5, 150.7, 147.1, 146.9, 139.5, 137.2, 135.4, 134.8, 132.9, 129.6, 129.5, 129.3, 128.8, 127.5, 127.3, 127.1, 127.0, 126.8, 122.7, 120.9, 112.4, 21.1. HRMS (ESI) m/z calculated for [C₄₂H₃₀N₆+H]⁺ 619.2605, found 619.2593.




3,5-Di-tert-butyl-1,7-bis(2,5-dimethylphenyl)-4-(quinolin-2-yl)-1,7-dihydrodipyrzolo[3,4-b:4',3'-e]pyridine (5af), 72 mg, 40%, yellow solid, m.p. 266–267°C, ^1H NMR (400 MHz, CDCl_3) δ 8.35 (d, $J = 8.3$ Hz, 1H), 8.25 (d, $J = 8.3$ Hz, 1H), 8.02 – 7.98 (m, 1H), 7.88 (ddd, $J = 8.4, 6.9, 1.4$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.73 (ddd, $J = 8.1, 6.9, 1.2$ Hz, 1H), 7.35 – 7.31 (m, 2H), 7.19 (d, $J = 7.8$ Hz, 2H), 7.08 (dd, $J = 7.8, 1.4$ Hz, 2H), 2.36 (s, 6H), 2.22 (s, 6H), 0.95 (s, 18H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.2, 153.9, 151.9, 146.8, 139.2, 137.3, 135.8, 135.6, 132.0, 131.0, 130.7, 129.8, 128.5, 128.0, 127.9, 127.8, 127.7, 125.4, 111.4, 34.5, 30.2, 20.9, 18.5. HRMS (ESI) m/z calculated for $[\text{C}_{40}\text{H}_{42}\text{N}_6+\text{H}]^+$ 607.3544, found 607.3530.



5ag

Diethyl 2,6-diphenyl-4-(quinolin-2-yl)pyridine-3,5-dicarboxylate (5ag), 37 mg, 25%, brown solid, m.p. 160–162°C, ^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, $J = 8.1$ Hz, 1H), 8.08 (d, $J = 8.1$ Hz, 1H), 7.90 – 7.86 (m, 1H), 7.78 – 7.68 (m, 5H), 7.64 – 7.57 (m, 2H), 7.46 – 7.41 (m, 6H), 3.87 (q, $J = 7.1$ Hz, 4H), 0.77 (t, $J = 7.1$ Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 157.3, 155.0, 147.7, 146.8, 139.3, 136.5, 130.1, 129.4, 129.1, 128.7, 128.3, 127.7, 127.3, 127.2, 127.1, 61.5, 13.4. HRMS (ESI) m/z calculated for $[\text{C}_{32}\text{H}_{26}\text{N}_2\text{O}_4+\text{H}]^+$ 503.1965, found 503.1957.



Diethyl 2,6-bis(4-methoxyphenyl)-4-(quinolin-2-yl)pyridine-3,5-dicarboxylate (5ah), 66 mg, 42%, yellow solid, m.p. 183–185°C, ^1H NMR (400 MHz, CDCl_3) δ 8.25 (d, $J = 8.5$ Hz, 1H), 8.09 (d, $J = 8.6$ Hz, 1H), 7.87 (d, $J = 8.1$ Hz, 1H), 7.76 – 7.72 (m, 1H), 7.71 – 7.67 (m, 4H), 7.62 – 7.55 (m, 2H), 6.99 – 6.94 (m, 4H), 3.90 (q, $J = 7.1$ Hz, 4H), 3.83 (s, 6H), 0.80 (t, $J = 7.1$ Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.0, 160.4, 156.4, 155.2, 147.6, 146.8, 136.3, 131.7, 130.0, 130.0, 129.3, 127.6, 127.1, 127.1, 125.9, 120.8, 113.7, 61.3, 55.2, 13.4. HRMS (ESI) m/z calculated for $[\text{C}_{34}\text{H}_{30}\text{N}_2\text{O}_6+\text{H}]^+$ 563.2177, found 563.2164.

5. ^1H -NMR and ^{13}C -NMR Spectra of Products

